159749-28-7

Basic information

• Product Name: AZETIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER
• Synonyms: AZETIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER;BOC-AZETIDINE-2-CARBOXYLIC ACID;1-N-BOC-AZETIDINE-2-CARBOXYLIC ACID;N-Boc-Azetidine-2-carboxylic acid;1-Boc-L-azetidine-2-carboxylic acid;1,2-Azetidinedicarboxylic acid, 1-(1,1-dimethylethyl) ester;1-Boc-azetidine-2-carboxylic acid;AZETIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER N-BOC-
• CAS NO: 159749-28-7
• Molecular Formula: C₉H₁₅NO₄
• Molecular Weight: 201.2197
• Product Categories: pharmacetical
• Mol File: 159749-28-7.mol

Chemical Properties

• Boiling Point: 321 °C at 760 mmHg
• Flash Point: 147.9 °C
• Appearance: /
• Density: 1.246 g/cm³
• Vapor Pressure: 6.35E-05mmHg at 25°C
• Refractive Index: 1.51
• Storage Temp.: 2-8°C
• PKA: 4.01±0.20(Predicted)
• CAS DataBase Reference: AZETIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: AZETIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER(159749-28-7)
• EPA Substance Registry System: AZETIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER(159749-28-7)

Safety Data

• Hazard Codes: Xi,N
• Statements: 36/37/38-50
• Safety Statements: 26-36-61-24/25
• RIDADR: UN3077
• WGK Germany: 3
• Hazardous Substances Data: 159749-28-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
AZETIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER is used as an intermediate in the synthesis of pharmaceutical compounds for its ability to contribute to the development of inhibitors and receptor antagonists.
Used in Polypeptide Synthesis:
AZETIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER is also used as a building block in the synthesis of polypeptides, which are essential in various biological and pharmaceutical applications.
Used in the Chemical Industry:
AZETIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER can be utilized in the chemical industry for the development of new compounds and materials, thanks to its versatile chemical properties and reactivity.

InChI:InChI=1/C9H15NO4/c1-9(2,3)14-8(13)10-5-4-6(10)7(11)12/h6H,4-5H2,1-3H3,(H,11,12)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 255882-72-5 azetidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 2517-04-6 Azetidine-2-carboxylic acid 
• 2133-34-8 (2S)-azetidine-2-carboxylic acid 

Downstream Products

• 174346-82-8 R,S-1-[(1,1-Dimethylethoxy)carbonyl]azetidine-2-methanol 
• 1219220-82-2 tert-butyl 2-carbamoylazetidine-1-carboxylate 
• 1400283-99-9 C₁₉H₂₃N₃O₄S 
• 1233146-26-3 (+/-)-azetidin-2-yl-(4-{3-methoxy-4-[7-(2-methoxyphenyl)pyrrolo[2,1-f][1,2,4]triazin-2-ylamino]phenyl}piperidin-1-yl)methanone 
• 255882-72-5 azetidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 850789-22-9 1-(tert-butoxycarbonyl)-2-(hydroxymethyl)-2-methylazetidine 

Relevant articles and documents

INHIBITORS OF ENCEPHALITIC ALPHAVIRUSES

Compounds of Formula I and Formula II: pharmaceutical compositions containing them, and use of the compounds as active ingredients to treat infection with alphavirus.

Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders

Dermatologic disorders such as atopic dermatitis arise from genetic and environmental causes and are complex and multifactorial in nature. Among possible risk factors, aberrant immunological reactions are one of the leading etiologies. Immunosuppressive agents including topical steroids are common treatments for these disorders. Despite their reliability in clinical settings, topical steroids display side effects, typified by skin thinning. Accordingly, there is a need for alternate effective and well-tolerated therapies. As part of our efforts to investigate new immunomodulators, we have developed a series of JAK inhibitors, which incorporate novel three-dimensional spiro motifs and unexpectedly possess both excellent physicochemical properties and antidermatitis efficacy in the animal models. One of these compounds, JTE-052 (ent-60), also known as delgocitinib, has been shown to be effective and well-tolerated in human clinical trials and has recently been approved in Japan for the treatment of atopic dermatitis as the first drug among Janus kinase inhibitors.

PYRAZOLOPYRIMIDINE PDE9 INHIBITORS

The present invention is directed to amino and alkyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such co

SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF

The present invention relates to compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more cysteine proteas

Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis

A high-throughput screen (HTS) was undertaken against the respiratory chain dehydrogenase component, NADH:menaquinone oxidoreductase (Ndh) of Mycobacterium tuberculosis (Mtb). The 11000 compounds were selected for the HTS based on the known phenothiazine Ndh inhibitors, trifluoperazine and thioridazine. Combined HTS (11000 compounds) and in-house screening of a limited number of quinolones (50 compounds) identified ～100 hits and four distinct chemotypes, the most promising of which contained the quinolone core. Subsequent Mtb screening of the complete in-house quinolone library (350 compounds) identified a further ～90 hits across three quinolone subtemplates. Quinolones containing the amine-based side chain were selected as the pharmacophore for further modification, resulting in metabolically stable quinolones effective against multi drug resistant (MDR) Mtb. The lead compound, 42a (MTC420), displays acceptable antituberculosis activity (Mtb IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM) and favorable pharmacokinetic and toxicological profiles.

QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS

Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof,and method of use thereof.

METABOTROPIC GLUTAMATE RECEPTORS 5 MODULATORS AND METHODS OF USE THEREOF

Compounds that modulate GluR5 activity and methods of using the same are disclosed.

SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME

The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2

2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY

A compound of formula (I): wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.

Application of Oppolzer's sultam in the synthesis of cyclic α-amino acids and β-amino acids

In this paper we describe the application of Oppolzer's sultam as a chiral auxiliary for the synthesis of cyclic α- and β2-amino acids. The key step of the synthesis is stereoselective alkylation of sultam-derived glycine and β-alanine Schiffs bases leading to diastereometrically pure products. Final compounds are obtained after mild acidic and next basic hydrolyses of auxiliary groups and can be directly converted into N-tert-butoxycarbonyl- or N-fluorenylmethoxycarbonyl derivatives useful in peptide synthesis. In the case of substrates alkylated with dihalogenoalkanes spontaneous cyclization occurring during removal of the auxiliary groups yields cyclic α-amino acids (proline homologues) with reasonable yield and stereoselectivity. Theoretical data explain the differences in tendency for cyclization between α- and β-amino acids.